gpt-dict.com

比菲德氏菌 BB536 Bifidobacterium longum BB536 × 嬰兒腸絞痛

結論：證據不足

綜合 L2 PubMed 搜尋與 L5b–L5e 四大臨床機構（Mayo、Cleveland、Harvard、AAP）的查證結果，找不到任何以 Bifidobacterium longum BB536 此一特定菌株針對嬰兒腸絞痛進行的 RCT 或系統性回顧。

U ⚫ U 未驗證 證據不足 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 🇹🇼 台灣在地警示
⚗️ 研究進行中：本主題證據仍在累積、尚無定論；部分介入屬試驗階段，未必已在台上市或可購得。

綜合 L2 PubMed 搜尋與 L5b–L5e 四大臨床機構（Mayo、Cleveland、Harvard、AAP）的查證結果，找不到任何以 Bifidobacterium longum BB536 此一特定菌株針對嬰兒腸絞痛進行的 RCT 或系統性回顧。

現有腸絞痛益生菌證據集中於 L. reuteri DSM17938、B. animalis lactis BB-12、B. longum CECT7894+P. pentosaceus CECT8330、B. longum KABP042+P. pentosaceus KABP041 等不同菌株；即便是同種 B. longum 的 CECT7894/KABP042 也屬於不同菌株，無法外推至 BB536。

Examine 與 NIH ODS 亦未對 BB536 此適應症提供任何證據評級，因此 strain-exact 證據完全缺位，僅能評為 U（證據不足）。

⚖️

評分透明度

所有分數由 7 層證據引擎計算，過程公開可查
原始分數 0.43
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
U · 證據不足
信心度
65%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧／統合分析

各層「支持此療效」的程度

分數越低＝該層越不支持
L11 AI 複核獨立判讀
0.20
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
L5 臨床機構權威立場
0.47
L1 Examine國際基準
0.50
不支持 中性 / 混合 支持
▸查看完整決策路徑（audit trail）
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.434
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 1 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Probiotics to prevent infantile colic
PMID: 30865287 2019 Cochrane Review n = 1,886
結論：No significant effect on preventing colic onset (RR 0.46, 95% CI 0.18-1.19), but daily crying time was reduced (MD -32.57 min/day, 95% CI -55.60 to -9.54), driven by L. reuteri (MD -44.26 min/day); GRADE certainty LOW.
🟢 高品質 政府資助 效應量：Colic onset RR 0.46 (NS); crying time MD -32.57 min/day (95% CI -55.60 to -9.54)
前往 PubMed
Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis
PMID: 29279326 2018 統合分析 n = 345
結論：Individual-participant-data MA of 4 double-blind RCTs: L. reuteri DSM17938 cut crying/fussing by -25.4 min/day at day 21 (95% CI -47.3 to -3.5); treatment success in BREASTFED infants only (IRR 1.7, 95% CI 1.4-2.2, NNT 2.6), no benefit in formula-fed.
🟢 高品質 混合資助 效應量：MD -25.4 min/day (95% CI -47.3 to -3.5); breastfed responders IRR 1.7 (NNT 2.6)
前往 PubMed
Probiotics for infantile colic: Is there evidence beyond doubt? A meta-analysis and systematic review
PMID: 37962097 2024 統合分析
結論：Probiotics overall reduced crying by ~51 min/day (p=0.001), strongest in exclusively breastfed infants (-74.28 min/day, p=0.0003); L. reuteri DSM17938 -64.66 min/day (p=0.03); evidence for formula-fed and caesarean-born infants was limited.
效應量：Overall MD -51 min/day (p=0.001); breastfed -74.28 min/day (p=0.0003)
前往 PubMed
Infantile Colic Treated With Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8330: A Randomized, Double-Blind, Placebo-Controlled Trial
PMID: 34568236 2021 Journal article n = 112
結論：B. longum CECT7894 + P. pentosaceus CECT8330 (1x10^9 CFU/day) shortened crying vs placebo at day 21 (14 vs 40 min/day, p<0.001), with day-21 responder rate 89.5% vs 64.3%; strain is B. longum CECT7894/KABP042, NOT BB536.
⚠️ 廠商資助 效應量：Day 21 crying 14 vs 40 min/day (p<0.001); responders 89.5% vs 64.3%
前往 PubMed
Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediococcus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM17938 in the management of infant colic: a randomized clinical trial
PMID: 39390276 2024 RCT (open-label) n = 112
結論：B. longum KABP042 + P. pentosaceus KABP041 (10^9 CFU/day) beat L. reuteri DSM17938 (10^8 CFU/day): day-14 responders 84.6% vs 59.3% (p=0.004), day-21 crying 29 vs 67 min/day (p=0.011); single-blind; strain is KABP042, NOT BB536.
⚠️ 廠商資助 效應量：Day 14 responders 84.6% vs 59.3% (p=0.004); day 21 crying 29 vs 67 min (p=0.011)
前往 PubMed
Probiotics in Term Infants: Clinical Impact of Infant-Type Bifidobacteria: A Systematic Review and Meta-analyses
PMID: 41082980 2025 系統性回顧
結論：Across 25 RCTs the primary benefit was eczema prevention (RR 0.78, 95% CI 0.68-0.90); for colic, only 1 of 7 studies (Giglione) showed reduced crying (MD -35.10 min/day, 95% CI -55.41 to -13.51), rest inconclusive; review EXPLICITLY EXCLUDED B. longum BB536 as not infant-type.
學術資助 效應量：Colic signal MD -35.10 min/day in 1/7 studies; eczema RR 0.78 (primary outcome, not colic)
前往 PubMed

L4a US FDA
支持
GRN No. 877 — Bifidobacterium longum BB536. Intended use: ingredient in term infant formula at a level of 1 x 10^8 CFU per gram of product. FDA closure date: December 26, 2019. FDA letter: 'FDA has no questions' regarding the safety of Bifidobacterium longum BB536 when used as described in the notice. (Earlier GRN 268 covered use in conventional foods/beverages.) 來源↗
L4b EU EFSA
謹慎
Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 3005) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Conclusion: Bifidobacterium longum BB536 does not improve… 來源↗
L4c UK NHS
謹慎
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
健康食品查驗登記審查採雙軌制，第一軌為「個案審查」，第二軌為「規格標準審查」，通過審查的產品會給予健康食品(小綠人)標章，第一軌的產品上標有「衛部健食字第A00000號」，第二軌的產品標有「衛部健食規字第000000號」。目前健康食品可以宣稱的保健功效項目共有13項，包括調節血脂、胃腸功能改善、護肝、免疫調節、骨質保健、不易形成體脂肪、抗疲勞、輔助調整過敏體質、調節血糖、延緩衰老、牙齒保健、促進鐵吸收、輔助調節血壓。 來源↗
L4e WHO
中性
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
中性
— 本適應症無對應資料
L5b Mayo Clinic
謹慎
Some studies have shown less crying time when babies with colic were treated with a bacterium called Lactobacillus reuteri. However, most experts agree that the study results don't support the use of probiotics to treat colic at this time. The studies have been done with small groups, and results have been mixed. Most Mayo Clinic pediatricians don't recommend the routine use of probiotics in in… 來源↗
L5c Cleveland Clinic
中性
— 本適應症無對應資料
L5d Harvard Health
中性
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
謹慎
Probiotics, gripe water or gas drops may be worth a try, but discuss it with your pediatrician first. 來源↗

PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽

台灣 PTT、Dcard、BabyHome、Mobile01 等社群幾乎沒有針對「BB536 株 × 嬰兒腸絞痛」的具體經驗分享。多數討論為通用「益生菌」或聚焦於 Biogaia 寶乖亞 (L. reuteri DSM17938) 為主，BB536 在台灣多被定位為成人腸道保健或多菌株嬰兒配方中的成分，並非腸絞痛首選；現有資訊多為品牌行銷文與代購商品頁，缺乏家長真實使用心得。

💬社群實感

資料不足

破解迷思 社群最常見的 3 個誤解
✓
事實誤以為所有「比菲德氏菌」都等同於 BB536 株
✓
事實把 BB536 與 Biogaia 寶乖亞 (L. reuteri) 混為一談，後者才是腸絞痛主要研究菌株
✓
事實認為日本品牌即代表臨床效果優於本土品牌
🏷️ 社群熱議品牌

依論壇被提及頻率，非銷售或品質排序。

  • 森永 Morinaga 好好菌
  • 大醫生技 BB536
  • ANNJACK 安納爵
  • Nucode 營養密碼
  • 太陽星 BB536
  • 樂亦康

⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

在台灣，健康食品可宣稱的保健功效包括「免疫調節」和「胃腸功能改善」等13項，產品所准許宣稱之保健功效取決於個別產品所提出科學驗證之結果。通過審查的產品會獲得健康食品標章，第一軌的產品上標有「衛部健食字第A00000號」。

代表來源 ↗
L10b · TFDA 法定身份 官方認定

Bifidobacterium longum is listed in the 可供食品使用原料彙整一覽表 (Approved Food Ingredient List) under the category of lactic acid bacteria (乳酸菌), and is approved for use as a food ingredient or in food processing.

來源 ↗

  • 餵食姿勢與安撫策略 (5S)
  • L. reuteri DSM 17938 (母乳寶寶)
✓ PMID 可查證引用皆附 NCBI PubMed 原始連結
🔬 6 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-09 claim_version: v8 engine_version: v1.0 claim_id: CLM-COND-infant-colic-INT-bifidobacterium-longum-bb536-001
查看 ClaimReview 結構化資料 (JSON-LD) 
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-infant-colic-INT-bifidobacterium-longum-bb536-001/",
  "datePublished": "2026-06-09",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "比菲德氏菌 BB536能改善嬰兒腸絞痛",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "alternateName": "證據不足 (Insufficient evidence)"
  }
}